Enanta Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Enanta Pharmaceuticals

25/11/2024 22:01

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.36​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of $-1.33.  The mean expectation of
seven analysts for the quarter was for a loss of $1.16 per
share. Wall Street expected results to range from $-1.50 to -70
cents per share.
    * Revenue fell 22.8% to $14.61 million from a year ago;
analysts
expected $17.93 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.36​.
    * The company reported a quarterly loss of $28.82 million.
    * Enanta Pharmaceuticals Inc shares had fallen by 9.8% this
quarter and lost 0.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $22.00 
This summary was machine generated from LSEG data November 25 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.16          -1.36          Missed
 Jun. 30 2024      -1.45          -1.07          Beat
 Mar. 31 2024      -1.30          -1.47          Missed
 Dec. 31 2023      -1.19          -1.58          Missed